Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

Bernard Escudier1, Jan Cosaert2, Sangeeta Jethwa21Unit&eacute; Immunoth&eacute;rapie, Institut Gustave Roussy, Villejuif, France; 2F. Hoffmann-La Roche Ltd, Basel, SwitzerlandAbstract: Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effectiv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bernard Escudier, Jan Cosaert, Sangeeta Jethwa
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/d19bb4fcab0d4f1794b552ac3168d89d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d19bb4fcab0d4f1794b552ac3168d89d
record_format	dspace
spelling	oai:doaj.org-article:d19bb4fcab0d4f1794b552ac3168d89d2021-12-02T00:56:52ZTargeted therapies in the management of renal cell carcinoma: role of bevacizumab1177-54751177-5491https://doaj.org/article/d19bb4fcab0d4f1794b552ac3168d89d2008-09-01T00:00:00Zhttp://www.dovepress.com/targeted-therapies-in-the-management-of-renal-cell-carcinoma-role-of-b-a2301https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Bernard Escudier1, Jan Cosaert2, Sangeeta Jethwa21Unit&eacute; Immunoth&eacute;rapie, Institut Gustave Roussy, Villejuif, France; 2F. Hoffmann-La Roche Ltd, Basel, SwitzerlandAbstract: Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effective option for first-line therapy for advanced and/or metastatic renal cell carcinoma (RCC). Two phase III trials clearly show significant improvements in progression-free survival and response rate in patients with treatment-na&iuml;ve metastatic RCC receiving bevacizumab combined with IFN compared with IFN. The dose of IFN, which was initiated at 9 MIU 3 times a week in these trials, can be reduced to effectively manage IFN-related side effects without compromising the efficacy of bevacizumab plus IFN. Bevacizumab has good tolerability with manageable side effects, both alone and in combination with other agents; the tolerability profile of bevacizumab in combination with IFN is consistent with the well-characterized and well-established profiles of these therapies. The tolerability of bevacizumab combined with IFN and the flexibility to manage IFN-related side effects are important considerations when selecting first-line therapy. With a number of options now available for RCC therapy, optimizing their use is a key consideration in improving patient benefit.Keywords: bevacizumab (Avastin&reg;), interferon alpha, efficacy, tolerability, renal cell carcinoma (RCC), low-dose interferon Bernard EscudierJan CosaertSangeeta JethwaDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 3, Pp 517-530 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Bernard Escudier Jan Cosaert Sangeeta Jethwa Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
description	Bernard Escudier1, Jan Cosaert2, Sangeeta Jethwa21Unit&eacute; Immunoth&eacute;rapie, Institut Gustave Roussy, Villejuif, France; 2F. Hoffmann-La Roche Ltd, Basel, SwitzerlandAbstract: Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effective option for first-line therapy for advanced and/or metastatic renal cell carcinoma (RCC). Two phase III trials clearly show significant improvements in progression-free survival and response rate in patients with treatment-na&iuml;ve metastatic RCC receiving bevacizumab combined with IFN compared with IFN. The dose of IFN, which was initiated at 9 MIU 3 times a week in these trials, can be reduced to effectively manage IFN-related side effects without compromising the efficacy of bevacizumab plus IFN. Bevacizumab has good tolerability with manageable side effects, both alone and in combination with other agents; the tolerability profile of bevacizumab in combination with IFN is consistent with the well-characterized and well-established profiles of these therapies. The tolerability of bevacizumab combined with IFN and the flexibility to manage IFN-related side effects are important considerations when selecting first-line therapy. With a number of options now available for RCC therapy, optimizing their use is a key consideration in improving patient benefit.Keywords: bevacizumab (Avastin&reg;), interferon alpha, efficacy, tolerability, renal cell carcinoma (RCC), low-dose interferon
format	article
author	Bernard Escudier Jan Cosaert Sangeeta Jethwa
author_facet	Bernard Escudier Jan Cosaert Sangeeta Jethwa
author_sort	Bernard Escudier
title	Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
title_short	Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
title_full	Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
title_fullStr	Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
title_full_unstemmed	Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
title_sort	targeted therapies in the management of renal cell carcinoma: role of bevacizumab
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/d19bb4fcab0d4f1794b552ac3168d89d
work_keys_str_mv	AT bernardescudier targetedtherapiesinthemanagementofrenalcellcarcinomaroleofbevacizumab AT jancosaert targetedtherapiesinthemanagementofrenalcellcarcinomaroleofbevacizumab AT sangeetajethwa targetedtherapiesinthemanagementofrenalcellcarcinomaroleofbevacizumab
_version_	1718403408597090304

Targeted therapies in the management of renal cell carcinoma: role of bevacizumab

Ejemplares similares